FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552993485> ?p ?o ?g. }

• W2552993485 endingPage "3217" @default.
• W2552993485 startingPage "3217" @default.
• W2552993485 abstract "Abstract Introduction: Cytogenetics is an independent prognostic factor in acute myeloid leukemia (AML). Molecular genetics including leukemia fusion gene, gene mutation and gene over expression are recognized to have significant impact on survival in patients with AML as well. In present study, the impact of cytogenetic and molecular markers on disease-free survival (DFS) of allogeneic hematopoietic stem cell transplantation (HSCT) for AML was investigated. Methods: Between April 2012 and December 2014, consecutive 345 patients with AML who underwent allogeneic HSCT in our center were analyzed retrospectively. All patients were either in poor-risk or in good-risk/intermediate-risk but with persistent minimal residual disease. The median age was 19 (1.8 to 64) years old. Children (≤14 years) were 96 (27.8%) cases and adults (>14 years) were 249 (72.2%) cases. Male to female was 200:145. The median disease course was 6 (1-64) months. Leukocyte count at diagnosis was < 30 x 109/L in 230 (66.7%) patients (low leukocyte) and ≥30 x 109/L in 115 (33.3%) cases (high leukocyte). Transplants at CR1, ≥CR2, and advanced disease were 168 (48.7%), 53 (15.4%) and 124 (35.9%), respectively. Donor sources were identical sibling (IS) in 45 (13.0%) cases, unrelated (UR) in 71 (20.6%) cases and haploidentical (HI) in 229 (66.4%) cases. Myeloablative conditioning regimens were administered with either Busulfan (Bu) plus Cyclophosphamide (Cy)/Fludarabine (Flu)-based in 285 (82.6%) patients or total body irradiation (TBI) plus Cy/Flu-based in 60 (17.4%) patients. Antithymocyte globulin was used in unrelated and haploidentical HSCT. Unmanipulated bone marrow and peripheral blood stem cells (PBSC) for IS and HI HSCT and PBSC for UR transplant were applied as the grafts. Cyclosporine, short-term Methotrexate, and Mycophenolate mofetil were employed for GVHD prophylaxis. Results: Univariate analysis showed that DFS after allogeneic HSCT in AML was not associated with patient age (children vs. adults, 70.3% vs. 69.4%, p=0.6), leukocyte count at diagnosis (low leukocyte vs. high leukocyte, 68.8% vs. 71.3%, p=0.8), donor source (IS vs. UD vs. HI, 77.3% vs. 76.8% vs. 65.8%, p=0.21), and conditioning regimen (Bu-based vs. TBI-based, 70.1% vs. 67.3%, p=0.45). Multivariate analysis indicated that disease status before HSCT was the only impact factor on DFS (CR1 vs. ≥CR2 vs. advanced disease, 81.6% vs. 70.0% vs. 53.1%, p<0.0001). Therefore, total 221 of 345 patients with AML in complete remission pre-conditioning were analyzed for impact of cytogenetic and molecular markers on survival after HSCT. DFS rates were 79.1%, 80.4%, 74.1% in good-risk, intermediate-risk, poor-risk cytogenetics groups (p=0.81), respectively. According to gene mutations, the DFS rates were 100% in CEBPA+, 91.6% in IDH1+/NPM1+, 85.7% in Flt3-ITD+, 81.5% in c-KIT+, 75.0% in no mutation, 70.2% in MLL-PTD+/ASXL1+/TET2+, 54.3% in Flt3-ITD+ with other mutations (p=0.42). According to gene expression, the DFS rates were 100% in DEK-CAN+, 100% in HOX11+/EVI1+, 84.8% in no abnormal gene expression, 83.3% in CBFb-MYH11+, 78.5% in WT1+, 76.5% in MLL+, 74.9% in AML1-ETO+, 0% in TLS-ERG+ (p=0.004). Conclusions: Under our HSCT protocol, disease status before transplant for the patients with AML has significant impact on DFS but not patient age, leukocyte count at diagnosis, donor source and conditioning regimen. Allogeneic HSCT has attenuated the influence of cytogenetics on DFS in patients with AML. Our preliminary data have shown that patients with CEBPA+, IDH1+/NPM1+, DEK-CAN+, HOX11+/NPM1+ have favorable survival, but patients with both Flt3-ITD+ and other gene mutations or with TLS-ERG+ have poor survival after allogeneic HSCT in AML. Disclosures No relevant conflicts of interest to declare." @default.
• W2552993485 created "2016-11-30" @default.
• W2552993485 creator A5013836476 @default.
• W2552993485 creator A5018040730 @default.
• W2552993485 creator A5023095202 @default.
• W2552993485 creator A5035705032 @default.
• W2552993485 creator A5045773186 @default.
• W2552993485 creator A5054435108 @default.
• W2552993485 creator A5055344816 @default.
• W2552993485 creator A5055550921 @default.
• W2552993485 creator A5065202324 @default.
• W2552993485 creator A5072543271 @default.
• W2552993485 creator A5075391403 @default.
• W2552993485 creator A5083455588 @default.
• W2552993485 creator A5085753584 @default.
• W2552993485 creator A5088706496 @default.
• W2552993485 date "2015-12-03" @default.
• W2552993485 modified "2023-10-01" @default.
• W2552993485 title "Impact of Cytogenetic and Molecular Markers on Disease-Free Survival of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia" @default.
• W2552993485 doi "https://doi.org/10.1182/blood.v126.23.3217.3217" @default.
• W2552993485 hasPublicationYear "2015" @default.
• W2552993485 type Work @default.
• W2552993485 sameAs 2552993485 @default.
• W2552993485 citedByCount "0" @default.
• W2552993485 crossrefType "journal-article" @default.
• W2552993485 hasAuthorship W2552993485A5013836476 @default.
• W2552993485 hasAuthorship W2552993485A5018040730 @default.
• W2552993485 hasAuthorship W2552993485A5023095202 @default.
• W2552993485 hasAuthorship W2552993485A5035705032 @default.
• W2552993485 hasAuthorship W2552993485A5045773186 @default.
• W2552993485 hasAuthorship W2552993485A5054435108 @default.
• W2552993485 hasAuthorship W2552993485A5055344816 @default.
• W2552993485 hasAuthorship W2552993485A5055550921 @default.
• W2552993485 hasAuthorship W2552993485A5065202324 @default.
• W2552993485 hasAuthorship W2552993485A5072543271 @default.
• W2552993485 hasAuthorship W2552993485A5075391403 @default.
• W2552993485 hasAuthorship W2552993485A5083455588 @default.
• W2552993485 hasAuthorship W2552993485A5085753584 @default.
• W2552993485 hasAuthorship W2552993485A5088706496 @default.
• W2552993485 hasConcept C104317684 @default.
• W2552993485 hasConcept C126322002 @default.
• W2552993485 hasConcept C143998085 @default.
• W2552993485 hasConcept C174475383 @default.
• W2552993485 hasConcept C203014093 @default.
• W2552993485 hasConcept C2777408962 @default.
• W2552993485 hasConcept C2778461978 @default.
• W2552993485 hasConcept C2778729363 @default.
• W2552993485 hasConcept C2779134260 @default.
• W2552993485 hasConcept C2779282312 @default.
• W2552993485 hasConcept C2779823535 @default.
• W2552993485 hasConcept C28328180 @default.
• W2552993485 hasConcept C2911091166 @default.
• W2552993485 hasConcept C30481170 @default.
• W2552993485 hasConcept C54355233 @default.
• W2552993485 hasConcept C71924100 @default.
• W2552993485 hasConcept C86803240 @default.
• W2552993485 hasConceptScore W2552993485C104317684 @default.
• W2552993485 hasConceptScore W2552993485C126322002 @default.
• W2552993485 hasConceptScore W2552993485C143998085 @default.
• W2552993485 hasConceptScore W2552993485C174475383 @default.
• W2552993485 hasConceptScore W2552993485C203014093 @default.
• W2552993485 hasConceptScore W2552993485C2777408962 @default.
• W2552993485 hasConceptScore W2552993485C2778461978 @default.
• W2552993485 hasConceptScore W2552993485C2778729363 @default.
• W2552993485 hasConceptScore W2552993485C2779134260 @default.
• W2552993485 hasConceptScore W2552993485C2779282312 @default.
• W2552993485 hasConceptScore W2552993485C2779823535 @default.
• W2552993485 hasConceptScore W2552993485C28328180 @default.
• W2552993485 hasConceptScore W2552993485C2911091166 @default.
• W2552993485 hasConceptScore W2552993485C30481170 @default.
• W2552993485 hasConceptScore W2552993485C54355233 @default.
• W2552993485 hasConceptScore W2552993485C71924100 @default.
• W2552993485 hasConceptScore W2552993485C86803240 @default.
• W2552993485 hasIssue "23" @default.
• W2552993485 hasLocation W25529934851 @default.
• W2552993485 hasOpenAccess W2552993485 @default.
• W2552993485 hasPrimaryLocation W25529934851 @default.
• W2552993485 hasRelatedWork W1734244994 @default.
• W2552993485 hasRelatedWork W1852421261 @default.
• W2552993485 hasRelatedWork W1972962779 @default.
• W2552993485 hasRelatedWork W1981974632 @default.
• W2552993485 hasRelatedWork W2010409307 @default.
• W2552993485 hasRelatedWork W2061660136 @default.
• W2552993485 hasRelatedWork W2062982294 @default.
• W2552993485 hasRelatedWork W2079279014 @default.
• W2552993485 hasRelatedWork W2082261439 @default.
• W2552993485 hasRelatedWork W2419419103 @default.
• W2552993485 hasRelatedWork W2568561383 @default.
• W2552993485 hasRelatedWork W2740686538 @default.
• W2552993485 hasRelatedWork W2793687898 @default.
• W2552993485 hasRelatedWork W2919847207 @default.
• W2552993485 hasRelatedWork W3013281346 @default.
• W2552993485 hasRelatedWork W3025031921 @default.
• W2552993485 hasRelatedWork W3092483516 @default.
• W2552993485 hasRelatedWork W3138897860 @default.
• W2552993485 hasRelatedWork W3159502021 @default.
• W2552993485 hasRelatedWork W567063424 @default.
• W2552993485 hasVolume "126" @default.

• next